Carrillo ER, Carrillo CJR, Carrillo CLD

Language: English
References: 24
Page: 128-131
PDF size: 260.24 Kb.

ABSTRACT

Amiodarone is an effective antiarrhytmic drug. It’s use may lead to several adverse effects, with lung toxicity being the most serious. We present the case of 85 year old patient with a history of chronic obstructive pulmonary disease who after 6 days of low dose of amiodarone therapy (200 mg daily) for treatment and prophylaxis of atrial fibrillation developed acute respiratory failure, hypoxemia and lung infiltrates. The patient failed to respond to diuretic, inotropic, mechanical ventilation and anti-infective therapy. Differential diagnosis of different causes of pulmonary infiltrates did not demonstrate any other abnormality therefore led to the diagnosis of amiodarone pulmonary toxicity. Pulmonary infiltrates and hypoxemia reversed with the suspension of amiodarone and treatment with steroids. Given the widespread use of amiodarone it’s important consider this serious adverse effect as a differential diagnosis in patients treated with amiodarone even at low doses and for short periods who present respiratory symtomatology, hypoxemia or pulmonary infiltrates.

REFERENCES

1. Wang T, Charette S, Smith MI. An unintended consequence: fatal amiodarone pulmonary toxicity in an older woman. J Am Med Dir Assoc 2006; 7: 510-3.

2. Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Cir J 2007; 71: 1610-6.

3. Vasallo P, Trohman RG. Prescribing amiodarone. JAMA 2007; 298: 1312-22.

4. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356: 935-41.

5. Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J 1983; 106: 906-15.

6. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-9.

7. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A Meta-analysis. J Am Coll Cardiol 1997; 30: 791-8.

8. Ou MC, Khoor A, Leventhal JP, Paterick TE, Burger CD. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003; 123: 646-51.

9. Fung RC, Chan WK, Chu CM, Yue CS. Low dose amiodaroneinduced lung injury. Int J Cardiol 2006; 113: 144-5.

10. Argyriou M, Hountis P, Antonopoulos N, Mathioudaki M. Acute fatal post-CABG low dose amiodarone lung toxicity. Asian Cardiovas Thorac Ann 2007; 15: 66-8.

11. Sunderj R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: A review of the risk and recommendations for surveillance. Can J Cardiol 2000; 16: 1435-50.

12. Kennedy JI, Myers JL, Plumb VJ. Amiodarone pulmonary toxicity: Clinical, radiologic and pathologic correlations. Arch Intern Med 1987; 147: 50-5.

13. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009; 16: 43-8.

14. Camus P, Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Clin Chest Med 2004; 25: 65-75.

15. Van Mieghem W, Coolen L, Malysse I. Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105: 1642-5.

16. Handschin AE, Lardinois D, Schneider D. Acute amiodarone induced pulmonary toxicity following lung resection. Respiratorion 2003; 70: 310-2.

17. Endoh Y, Hanai R, Uto K. Diagnostic usefulness of KL-6 measurements in patients with pulmonary complications after administration of amiodarone. J Cardiol 2000; 35: 121-7.

18. Ott MC, Khoor A, Leventhal JP. Pulmonary toxicity in patients receiving low dose amiodarone. Chest 2006; 123: 646-51.

19. Kuhlman JE, Teigen C, Ren H. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990; 177: 121-5.

20. Oyama N, Oyama N, Yokoshiki H. Detection of amiodarone induced pulmonary toxicity in supine and prone position: High resolution computed tomography study. Cir J 2005; 69: 466-70.

21. Pitcher WD. Southwestern Internal Medicine Conference: Amiodarone pulmonary toxicity. Am J Med Sci 1992; 393: 206-12.

22. Morera J, Vidal R, Morell F. Amiodarone and pulmonary fibrosis. Eur J Clin Pharm 1983; 24: 591-3.

23. Kosseifi SG, Halawa A, Bailey B, Micklewright M. Reduction of amioarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ther Adv Respir Dis 2009; 3: 289-94.

24. Nikaido A, Tada T, Nakamura K, Murakawi M, Banba K, Nishii N, et al. Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. Int J Cardiol 2010; 140: 328-35.